Please assess the completion status of the following clinical trial:

Trial Title: A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed relapsed/refractory lymphoid malignancies~* Previously treated with at least 2 therapeutic regimens~* ECOG performance \< 2.~* Life expectancy of at least 3 months~* Adequate renal function~* Adequate hematologic status~* Adequate liver function~* Transfusion independent~Exclusion Criteria:~* Received other therapy (biological or drug) to treat cancer within 4 weeks prior to starting treatment with HGS1029 or who exhibit persistent clinical evidence of cancer treatment toxicity~* The use of systemic corticosteroids within 1 week of starting treatment with HGS1029~* Evidence of active bacterial, viral or fungal infection within 2 weeks before starting treatment with HGS1029~* Known HIV infection~* Positive for hepatitis B surface antigen or positive hepatitis C antibody~* Grade 2 or greater neuropathy~* Pregnant female or nursing mother~* Males or females who do not agree to use effective contraception during the study and through at least 30 days after the last dose of HGS1029

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HGS1029 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).